 Plant-based biotech company 22nd Century Group, Inc. NASDAQ:XXII reported its results on Thursday for the third quarter ended September 30, revealing net sales of 7.8 million for the period, up 6.9 from the prior years period. Moreover, its year-to-date net sales totaled 23 million, up 11 from the corresponding period of last year. 